Vitamin D binding protein as a serum biomarker of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 43, Issue 1, 2014, Pages 37-45

  Bishnoi, Ram J ^a   Palmer, Raymond F ^a   Royall, Donald R ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Geriatric Research   (United States)

Author keywords

Dementia; serum biomarker; vitamin D binding protein

Indexed keywords

BIOLOGICAL MARKER; VITAMIN D BINDING PROTEIN;

AGED; ALZHEIMER DISEASE; BLOOD; BLOOD ANALYSIS; COHORT ANALYSIS; FACTORIAL ANALYSIS; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; UNITED STATES;

AGED; ALZHEIMER DISEASE; BIOMARKERS; BLOOD CHEMICAL ANALYSIS; COHORT STUDIES; DATASETS AS TOPIC; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; TEXAS; VITAMIN D-BINDING PROTEIN;

EID: 84908666698     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140042     Document Type: Article

References (49)

1. GressnerOA, SchifflersMC,KimP, Heuts L, Lahme B, Gressner AM (2009) Questioning the role of actinfree Gc-Globulin as actin scavenger in neurodegenerative central nervous system disease: Relationship to S-100B levels and blood-brain barrier function. Clin Chim Acta 400, 86-90.
2. Meier U, Gressner O, Lammert F, Gressner AM (2006) Gcglobulin: Roles in response to injury. Clin Chem 52, 1247-1253.
3. Speeckaert M, Huang G, Delanghe JR, Taes YE (2006) Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 372, 33-42.
4. Lee WM, Galbraith RM (1992) The extracellular actinscavenger system and actin toxicity. N Engl J Med 326, 1335-1341.
5. Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW (1990) Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci U S A 87, 1381-1385.
6. Binder R, Kress A, Kan G, Herrmann K, KirschfinkM(1999) Neutrophil priming by cytokines and vitamin D binding protein (Gc-globulin): Impact on C5a-mediated chemotaxis, degranulation and respiratory burst. Mol Immunol 36, 885-892.
7. Haddad JG (1995) Plasma vitamin D-binding protein (Gcglobulin): Multiple tasks. J Steroid Biochem Mol Biol 53, 579-582.
8. Moon M, Song H, Hong HJ, NamDW, ChaMY,OhMS,Yu J, Ryu H, Mook-Jung I (2013) Vitamin D-binding protein interacts with Abeta and suppresses Abeta-mediated pathology. Cell Death Differ 20, 630-638.
9. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ (2008) CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 129, 526-529.
10. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9, 293-348.
11. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimers disease. Ann Neurol 61, 120-129.
12. Liao PC, Yu L, Kuo CC, Lin C, Kuo YM (2007) Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimers disease. Proteomics Clin Appl 1, 506-512.
13. OBryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R, Texas Alzheimers Research Consortium (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67, 1077-1081.
14. Witte MM, Trzepacz P, Case M, Yu P, Hochstetler H, Quinlivan M, Sundell K, Henley D (2014) Association between clinical measures and florbetapir F18 PET neuroimaging in mild or moderate Alzheimers disease dementia. J Neuropsychiatry Clin Neurosci. doi: 10.1176/appi.neuropsych.12120402
15. Cohen J (1983) The cost of dichotomization. Appl Psychol Meas 7, 249-253.
16. Kreiner S (1989) Statistical analysis of complex health and social data. Soc Sci Med 29, 253-258.
17. Royall DR, Palmer RF (2012) Getting Past "g": Testing a new model of dementing processes in persons without dementia. J Neuropsychiatry Clin Neurosci 24, 37-46.
18. Royall DR, Palmer RF, Texas Alzheimers Research Care (2013) Validation of a latent construct for dementia casefinding in Mexican-Americans. J Alzheimers Dis 37, 89-97.
19. Royall DR, Palmer RF, Texas Alzheimers Research, Care, Consortium (2013) Does ethnicity moderate dementias biomarkers? Neurobiol Aging 35, 336-344.
20. Royall DR, Palmer RF, OBryant SE, Texas Alzheimers Research, Care, Consortium (2012)Validation of a latent variable representing the dementing process. J Alzheimers Dis 30, 639-649.
21. Spearman C,Wynn Jones LL (1951) Human Ability.Macmillan & Co., London.
22. Royall DR, Palmer RF, Texas Alzheimers Research Care (2013) Validation of a latent construct for dementia casefinding in Mexican-Americans. J Alzheimers Dis 37, 89-97.
23. Royall DR, Palmer RF, Texas Alzheimers Research, Care, Consortium (2014) Does ethnicity moderate dementias biomarkers? Neurobiol Aging 35, 336-344.
24. OBryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum CM, Doody R, Fairchild T, Adams P,Wilhelmsen K, Diaz-Arrastia R, Texas Alzheimers Research and Care Consortium (2011) A blood-based algorithm for the detection of Alzheimers disease. Dement Geriatr Cogn Disord 32, 55-62.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 34, 939-944.
26. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
27. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566-572.
28. Waring S, OBryant SE, Reisch JS, Diaz-Arrastia R, Knebl J, Doody R, for the TARCC (2008) The Texas Alzheimers Research Consortium longitudinal research cohort: Study design and baseline characteristics. Texas Pub Health J 60, 9-13.
29. Arbuckle JL (2006) Analysis of Moment Structures-AMOS.
30. Palmer RF, Royall DR (2010) Missing data? Plan on it! J Am Geriatr Soc 58(Suppl 2), S343-S348.
31. Muthen B, Tam T, Muthen L, Stolzenberg R, Hollis M (1993) Latent variable modeling in the LISCOMP framework: Measurement of attitudes towards career choice. In New Directions in Attitude Measurement, Krebs D, Schmidt P, eds. Walter de Gruyter, Berlin, Germany, pp. 277-290.
32. Muthen BO (1989) Dichotomous factor analysis of symptom data. Sociol Meth Res 18, 19-65.
33. Muthen BO (1979) A structural model with latent variables. J Am Stat Assoc 74, 807-811.
34. Bollen KA, Long JS (1993) Testing Structural Equation Models, Sage Publications, Thousand Oaks, CA.
35. Wheaton B, Muthen B, Alwin D, Summers G (1977) Assessing reliability and stability in panel models. In Sociological Methodology, Heise DR, ed. Jossey-Bass, Inc., San Francisco, pp. 84-136.
36. Bentler PM (1990) Comparative fit indexes in structural models. Psychol Bull 107, 238-246.
37. Browne M, Cudeck R (1993) Alternative ways of assessing model fit. In Testing Structural Equation Models, Bollen KA, Long JS, eds. Sage Publications, Thousand Oaks, CA, pp. 136-162.
38. Bentler PM, Bonnet DC (1980) Significance tests and goodness of fit in the analysis of covariance structures. Psychol Bull 88, 588-606.
39. Royall DR, Palmer RF (2013) Alzheimers disease pathology does not mediate the association between depressive symptoms and subsequent cognitive decline. Alzheimers Dement 9, 318-325.
40. Royall DR, Palmer RF, Vidoni ED, Honea RA, Burns JM (2012) The default mode network and related right hemisphere structures may be the key substrates of dementia. J Alzheimers Dis 32, 467-478.
41. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA (2005) Molecular, structural, and functional characterization of Alzheimers disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25, 7709-7717.
42. Moon M, Song H, Hong HJ, NamDW, ChaMY,OhMS,Yu J, Ryu H, Mook-Jung I (2013) Vitamin D-binding protein interacts with Abeta and suppresses Abeta-mediated pathology. Cell Death Differ 20, 630-638.
43. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R,Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology 73, 754-760.
44. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, De-Kosky ST (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65, 557-568.
45. Royall DR, Palmer RF (2015) Ethnicity moderates dementias biomarkers. J Alzheimers Dis doi: 10.3233/JAD-140264
46. Branisteanu DD, Mathieu C, Bouillon R (1997) Synergism between sirolimus and 1,25-dihydroxyvitamin D3 in vitro and in vivo. J Neuroimmunol 79, 138-147.
47. Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G (1998) Apolipoprotein E, transthyretin and actin in the CSF of Alzheimers patients: Relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett 425, 225-228.
48. Paris D, Ait-Ghezala G, Mathura VS, Patel N, Quadros A, Laporte V, Mullan M (2005) Anti-angiogenic activity of the mutant Dutch A(beta) peptide on human brain microvascular endothelial cells. Brain Res Mol Brain Res 136, 212-230.
49. Raymond A, Ensslin MA, ShurBD(2009) SED1/MFG-E8:A bi-motif protein that orchestrates diverse cellular interactions. J Cell Biochem 106, 957-966.